Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Do Young Kim

doi:10.3350/cmh.2017.0107

Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?

Department of Internal Medicine

Research output: Contribution to journal › Editorial › peer-review

Original language	English
Pages (from-to)	123-124
Number of pages	2
Journal	Clinical and Molecular Hepatology
Volume	23
Issue number	2
DOIs	https://doi.org/10.3350/cmh.2017.0107
Publication status	Published - 2017 Jun 1

All Science Journal Classification (ASJC) codes

Hepatology
Molecular Biology

Access to Document

10.3350/cmh.2017.0107

Cite this

@article{e5fd48305aad4ebcabac6ebcb6be9ab5,

title = "Can metronomic chemotherapy be an alternative to sorafenib in advanced hepatocellular carcinoma?",

author = "Kim, {Do Young}",

year = "2017",

month = jun,

day = "1",

doi = "10.3350/cmh.2017.0107",

language = "English",

volume = "23",

pages = "123--124",

journal = "Clinical and molecular hepatology",

issn = "2287-2728",